Detalles de la búsqueda
1.
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Blood
; 140(10): 1104-1118, 2022 09 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35878001
2.
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Cancer Immunol Immunother
; 72(7): 2499-2512, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37041225
3.
Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
Immunol Rev
; 270(1): 193-208, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26864113
4.
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Cancer Immunol Immunother
; 72(7): 2513-2514, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37154851
5.
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
Blood
; 123(4): 554-61, 2014 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24311721
6.
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Blood
; 123(3): 356-65, 2014 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-24300852
7.
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.
Proc Natl Acad Sci U S A
; 107(28): 12605-10, 2010 Jul 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-20616015
8.
Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
Cancer Immunol Immunother
; 58(1): 95-109, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18594818
9.
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer.
Oncoimmunology
; 8(12): e1674605, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31741778
10.
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
J Immunother Cancer
; 6(1): 116, 2018 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30396365
11.
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
Oncogene
; 37(39): 5269-5280, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29855615
12.
The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
PLoS One
; 10(8): e0135945, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26305211
13.
Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
Mol Cancer Ther
; 13(6): 1549-57, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24674885
14.
Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
Mol Cancer Ther
; 11(12): 2664-73, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23041545
15.
Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
J Immunother
; 32(4): 341-52, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19342971
16.
Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
J Immunother
; 32(5): 452-64, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19609237
17.
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Cancer Res
; 68(1): 143-51, 2008 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18172306
18.
Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3.
Cancer Immunol Immunother
; 55(7): 785-96, 2006 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16187083
Resultados
1 -
18
de 18
1
Próxima >
>>